Validating New Tuberculosis Computational Models with Public Whole Cell Screening Aerobic Activity Datasets

ABSTRACTPurposeThe search for small molecules with activity against Mycobacterium tuberculosis (Mtb) increasingly uses high throughput screening and computational methods. Several public datasets from the Collaborative Drug Discovery Tuberculosis (CDD TB) database have been evaluated with cheminformatics approaches to validate their utility and suggest compounds for testing.MethodsPreviously reported Bayesian classification models were used to predict a set of 283 Novartis compounds tested against Mtb (containing aerobic and anaerobic hits) and to search FDA approved drugs. The Novartis compounds were also filtered with computational SMARTS alerts to identify potentially undesirable substructures.ResultsUsing the Novartis compounds as a test set for the Bayesian models demonstrated a >4.0-fold enrichment over random screening for finding aerobic hits not in the computational models (N = 34). A 10-fold enrichment was observed for finding Mtb active compounds in the FDA drugs database. 85.9% of the Novartis compounds failed the Abbott SMARTS alerts, a value substantially higher than for known TB drugs. Higher levels of failures of SMARTS filters from different groups also correlate with the number of Lipinski violations.ConclusionsThese computational approaches may assist in finding desirable leads for Tuberculosis drug discovery.

[1]  Gautam R. Desiraju,et al.  A Virtual Screening Approach for Thymidine Monophosphate Kinase Inhibitors as Antitubercular Agents Based on Docking and Pharmacophore Models. , 2005 .

[2]  Ying Zhang,et al.  The magic bullets and tuberculosis drug targets. , 2005, Annual review of pharmacology and toxicology.

[3]  A. Ghose,et al.  Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods , 1998 .

[4]  Antony J. Williams,et al.  Free online resources enabling crowd-sourced drug discovery , 2009 .

[5]  Joel S. Freundlich,et al.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. , 2011, Trends in Microbiology.

[6]  Sean Ekins,et al.  Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5) , 2007, Drug Metabolism and Disposition.

[7]  Lynn Rasmussen,et al.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. , 2009, Tuberculosis.

[8]  Sean Ekins,et al.  When pharmaceutical companies publish large datasets: an abundance of riches or fool's gold? , 2010, Drug discovery today.

[9]  Sean Ekins,et al.  Meta-analysis of molecular property patterns and filtering of public datasets of antimalarial “hits” and drugs , 2010 .

[10]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[11]  R. Reynolds,et al.  High Throughput Screening for Inhibitors of Mycobacterium tuberculosis H 37 Rv , 2012 .

[12]  Lynn Rasmussen,et al.  Antituberculosis activity of the molecular libraries screening center network library. , 2009, Tuberculosis.

[13]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[14]  Robert A. Field,et al.  New Small-Molecule Synthetic Antimycobacterials , 2005, Antimicrobial Agents and Chemotherapy.

[15]  Brian Hudson,et al.  Strategic Pooling of Compounds for High-Throughput Screening , 1999, J. Chem. Inf. Comput. Sci..

[16]  Jean M. Severin,et al.  Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance. , 2007, Chemical research in toxicology.

[17]  Sean Ekins,et al.  A collaborative database and computational models for tuberculosis drug discovery. , 2010, Molecular bioSystems.

[18]  James F Blake,et al.  Identification and evaluation of molecular properties related to preclinical optimization and clinical fate. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).

[19]  Sean Ekins,et al.  Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. , 2010, Chemical research in toxicology.

[20]  Sean Ekins,et al.  Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. , 2010, Molecular bioSystems.

[21]  Pedro M Alzari,et al.  Rising standards for tuberculosis drug development. , 2008, Trends in pharmacological sciences.

[22]  Sarah R. Langdon,et al.  Predicting cytotoxicity from heterogeneous data sources with Bayesian learning , 2010, J. Cheminformatics.

[23]  Jeffrey R. Huth,et al.  Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups , 2007, J. Comput. Aided Mol. Des..

[24]  Philip Prathipati,et al.  Global Bayesian Models for the Prioritization of Antitubercular Agents , 2008, J. Chem. Inf. Model..

[25]  Renaldo Mendoza,et al.  ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens. , 2005, Journal of the American Chemical Society.

[26]  R. Buxton,et al.  New anti-tuberculosis agents amongst known drugs. , 2009, Tuberculosis.

[27]  M. Matsumoto,et al.  OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice , 2006, PLoS medicine.

[28]  Thomas R Ioerger,et al.  Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening. , 2008, Journal of medicinal chemistry.

[29]  Sean Ekins,et al.  Essential Metabolites of Mycobacterium tuberculosis and Their Mimics , 2011, mBio.

[30]  Tudor I. Oprea,et al.  Is There a Difference Between Leads and Drugs? A Historical Perspective. , 2001 .

[31]  Clifton E. Barry,et al.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis , 2000, Nature.

[32]  Ajay,et al.  Recognizing molecules with drug-like properties. , 1999, Current opinion in chemical biology.